RodneyPRocconiMD
Obstetrics & Gynecology • Mobile, ALGynecologic Oncology
Professor of Gynecologic Oncology, University of Alabama at Birmingham Associate Director, Infirmary Cancer Care Director of Research, Infirmary Cancer Care Specializing in preventing, diagnosing, and treating gynecological cancers
Dr. Rocconi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1660 Springhill Avenue
Mobile, AL 36640Phone+1 251-410-1010Fax+1 251-665-8010
Summary
- Dr. Rodney P. Rocconi is a Gynecologic Oncologist, specializing in preventing, diagnosing and treating gynecological cancers. He completed a Fellowship at the University of Alabama at Birmingham in Birmingham, AL. He is an Associate Director for Clinical Research
Education & Training
University of Alabama Medical CenterResidency, Obstetrics and Gynecology, 2000 - 2004
University of Alabama School of MedicineClass of 2000- University of Alabama Medical CenterFellowship, Gynecologic Oncology
Certifications & Licensure
MS State Medical License 2023 - 2025
AL State Medical License 2001 - 2024- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
- Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29
- Join now to see all
Publications & Presentations
PubMed
- 30 citationsPlatinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management.Mohammad Aslam Khan, Kunwar Somesh Vikramdeo, Sarabjeet Kour Sudan, Seema Singh, Annelise M. Wilhite
Seminars in Cancer Biology. 2021-08-18 - 15 citationsOvercoming technical challenges with robotic surgery in gynecologic oncologyMichael A. Finan, Rodney P. Rocconi
Surgical Endoscopy. 2010-06-01 - 64 citationsSecond-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, ...Gottfried E. Konecny, Neil Finkler, Agustin A. Garcia, Domenica Lorusso, Paula S. Lee
The Lancet. Oncology. 2015-06-01
Press Mentions
Gradalis to Host Key Opinion Leader Webinar on Unmet Medical Needs in Ovarian Cancer and the Company’s Immuno-Oncology Treatment, Vigil®September 28th, 2022- 14th Annual GO Run 5K Stays Virtual for 2021August 17th, 2021
- Vaccine Maintenance Improves Relapse-Free Survival in BRCA Wild-Type Ovarian CancerMay 6th, 2020
- Join now to see all
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
